https://www.selleckchem.com/pr....oducts/peficitinb-as
Surgical resection is the therapy of choice in head and neck paraganglioma but is associated with considerable morbidity. For treatment of inoperable or progressive disease, less aggressive adjuvant options are warranted. This study assessed effectiveness and safety of peptide receptor radionuclide therapy (PRRT) with lutetium-177-DOTATATE for head and neck paraganglioma with emphasis on response assessment. A retrospective analysis of 7 patients with head and neck paraganglioma treated with PPRT between May 2014
Like
Comment
Share
